MA
MAZE
Methodology breakdown computing — it will appear here on its own.
Maze Therapeutics Inc. (MAZE) was screened and our screen declined to rate it, so we publish no verdict, per our secondary compliance provider (last assessed 2026-08-25). See the full ratio breakdown and business-activity screen below for the reasoning.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for MAZE — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 34.90 | NEUTRAL |
| Stochastic %K (14) | 12.83 | BUY |
| CCI (20) | -138.89 | BUY |
| Williams %R (14) | -87.17 | BUY |
| MACD (12,26,9) | -0.40 | SELL |
| ROC (10) | -16.09 | SELL |
| Momentum (10) | -4.76 | SELL |
| EMA (10) | 26.29 | SELL |
| SMA (10) | 26.37 | SELL |
| EMA (20) | 27.07 | SELL |
| SMA (20) | 27.67 | SELL |
| EMA (30) | 27.39 | SELL |
| SMA (30) | 27.66 | SELL |
| EMA (50) | 27.73 | SELL |
| SMA (50) | 28.41 | SELL |
| EMA (100) | 28.82 | SELL |
| SMA (100) | 27.11 | SELL |
| EMA (200) | 31.80 | SELL |
| SMA (200) | 34.07 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
About Maze Therapeutics Inc.
Healthcare · Biotechnology
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Background via Yahoo Finance — informational, not part of the verdict.
Weak — low conviction, small size or skip
SMC — Top Down
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 62 |
| ⏰ 4H | BEARISH | 35 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Peer Movement
Peer movement computing — it will appear here on its own.
Insider Activity (90d)
CLUSTER SELL 0 buys · 15 sells
Recent: Coloma Jason V sold 342944 sh @ $26.00 (2026-06-22); Coloma Jason V sold 287171 sh @ $30.44 (2026-07-01); Coloma Jason V sold 288768 sh @ $29.95 (2026-07-01)
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.